Skip to content
OpenCapital
Get started

Travere Therapeutics, Inc. TVTX Enterprise value

Enterprise value at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$109.92B-9.5%
LQD
Liquidia CorporationLQDA
$3.11B+184%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$16.77B+178%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$5.2B+77.3%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$3.81B-14.5%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$2.27B-4.1%

Other financials

Income statement

See full
Revenue$127.2M+55.6%
Gross profit$125.2M+62.5%
Operating income-$36.9M+13.5%
Net income-$37.1M+10.0%
EPS (diluted)-$0.40+14.9%

Balance sheet

See full
Cash & equivalents$78.4M+26.6%
Total debt$15.6M-82.6%
Total equity$98.7M+201%
Total assets$555.2M+1.2%

Cash flow

See full
Operating cash flow-$40.4M+4.3%
CapEx$140.0K—
Free cash flow-$42.5M+28.1%

Valuation

See full
Market cap$5.13B+72.3%

Profitability

See full
Gross margin98.6%+2.6pp
Operating margin-10.6%-5.0pp
Net margin-20.3%-9.5pp
FCF margin-133.9%-34.4pp

Returns & leverage

See full
Return on equity-706%-1,302pp
Debt / equity0.2×-2.6×
Current ratio3.1×+1.1×

Where this comes from

Calculated from Travere Therapeutics, Inc.’s reported figures.

$2.7Bmarket cap+$15.6Mtotal debt−$78.4Mcash and equivalents=$2.68B

The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Travere Therapeutics, Inc.'s enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Travere Therapeutics, Inc.'s enterprise value?
Travere Therapeutics, Inc. (TVTX) reported enterprise value of $2.68B in Q1 2026.
How has Travere Therapeutics, Inc.'s enterprise value changed year-over-year?
Travere Therapeutics, Inc.'s enterprise value increased by 65.5% year-over-year, from $1.62B to $2.68B.
What is the long-term trend for Travere Therapeutics, Inc.'s enterprise value?
Over 5 years (2020 to 2025), Travere Therapeutics, Inc.'s enterprise value has grown at a 17.6% compound annual growth rate (CAGR), from $1.48B to $3.34B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.